FDA to fast-track review of BMS' CAR-T, ahead of shareholder...

Speculators who bought into a risky three-drug bet are still on track for a payout following Celgene's merger with Bristol-Myers Squibb, after the FDA agreed to fast-track its review of a n

Calibr and AbbVie's switchable cancer CAR-T begins clinical ...

California biotech Calibr and research partner AbbVie have clearance to start clinical trials of a new CAR-T technology, involving “switchable” cells that aim to eliminate the life-threaten

EMA starts review of second CAR-T from Gilead’s Kite unit

BMS files first drug from triple bet with Celgene shareholde...

Bristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” with former investors in Celgene that could pay out billions if they all successfully make i

Gilead to file new CAR-T, setting up potential mid-2020 laun...

Gilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing some impressive response rates in patients with relapsed or refractory mantle cell lymphoma.

Understanding the evolving CAR-T market

In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy.